CONTERA PHARMA A/S: Financial statements 2024
CVR: 33062214
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -54,083,946 and a net result of DKK -69,213,744 compared with DKK -71,320,299 the year before. Equity in the 2024 report amounted to DKK 54,388,190. The solvency ratio was 85.5%. The company had 19 employees in the financial year.
- Gross Profit
- DKK -54,083,946
- Profit/Loss
- DKK -69,213,744
- Equity
- DKK 54,388,190
- Total Assets
- DKK 63,609,782
- Employees
- 19
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -54.1 mio. | -69.2 mio. | 54.4 mio. | 19 |
| 2023 | - | -59 mio. | -71.3 mio. | 86.3 mio. | 17 |
| 2022 | - | -44.8 mio. | -56.9 mio. | 106.6 mio. | 14 |
| 2021 | - | -24.2 mio. | -31.5 mio. | 163.4 mio. | 13 |
| 2020 | - | -9.7 mio. | -12.3 mio. | 195 mio. | 4 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 1, 2024, Mahmoud Mahmoudian has joined the board of directors of CONTERA PHARMA A/S.
As of December 1, 2024, Soo Yeon Park has joined the board of directors of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2023. Gross profit came to DKK -58,993,909, and the net result was DKK -71,320,299.
As of April 1, 2024, is registered as an owner of CONTERA PHARMA A/S with an ownership share of 90%.
As of March 1, 2024, Paul Ejnar Gremaud Kristjansen has joined the board of directors of CONTERA PHARMA A/S.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.